Navigation Links
National Survey Shows Patients are Unaware of Serious Heart Risks of Triglycerides

Results of a national survey from the National Lipid Association (NLA) demonstrate that patients—including those at greatest risk—are woefully// unaware of the cardiovascular risks associated with unhealthy levels of triglycerides, a fat found in the blood. The Moving Beyond Cholesterol survey, which included 2,089 patients and 510 doctors, revealed that the overwhelming majority of physicians felt patients did not understand triglycerides and were not aware of the differences between triglycerides and cholesterol, or the independent risks unhealthy levels of triglycerides may pose to heart health.

Triglycerides are a type of fat (or lipid) found in the blood that is produced by the body and ingested from food. They are measured as part of a standard lipid blood test. Elevated triglycerides are linked to serious illnesses, including heart disease, kidney disease and pancreatitis. Nearly 9 out of 10 doctors surveyed agreed that they are an independent risk factor for heart disease, as outlined by the National Cholesterol Education Program. So-called “good,” or HDL cholesterol, and “bad,” or LDL cholesterol are other types of lipids. The risk is a widespread matter of concern, with 100 million Americans living with unhealthy lipid levels, according to the American Heart Association.

“These findings clearly show that we, as physicians, need to do a more thorough job of being sure our patients understand the cardiovascular risk of unhealthy lipid levels, including often-ignored triglycerides,” said Jerome D. Cohen, M.D., director of Preventive Cardiology Programs at St. Louis University Health Sciences Center and chairman of the National Lipid Association Consumer Affairs Committee. “A first step is for doctors to make sure they understand current guidelines, as those surveyed felt they were less familiar with triglyceride guidelines than with those for ‘good’ or ‘bad’ cholesterol.”

While 83 percent of physicians knew that national gui
'"/>




Page: 1 2 3

Related medicine news :

1. National Lung Study in the process
2. Indian Nationals with Foreign Medical Degrees can now practice in India
3. Hepatitis B Vaccine To Be Included In National Immunization Programme
4. UK Govt Says On Course For National Chlamydia Screening
5. Mexico and US border attain a new outlook due to BiNational Sustainability Laboratory
6. India extends National TB Control Program
7. President and Founder of National Obesity Forum Resigns
8. Hwang Woo Suk Suspended By Seoul National University
9. Indian National in Saudi Jail will be released soon
10. National Women and Girls HIV/AIDS Awareness Day
11. Calcutta National Medical College Strike Continues Unabated
Post Your Comments:
Breaking Medicine Technology:Hill-Rom Announces Appointment of James R. Giertz to Board of Directors 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 2Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 3Catholics for Choice Statement on Healthcare Reform Bill 60931 1Catholics for Choice Statement on Healthcare Reform Bill 60931 2Findings show nanomedicine promising for treating spinal cord injuries 10653 1Findings show nanomedicine promising for treating spinal cord injuries 10653 2Findings show nanomedicine promising for treating spinal cord injuries 10653 3APHA Applauds Prevention and Wellness Provisions in House Health Reform Bill 60929 1APHA Applauds Prevention and Wellness Provisions in House Health Reform Bill 60929 2